These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

181 related articles for article (PubMed ID: 17688232)

  • 1. A lesson from the EPO mess: stop the cost shifting.
    Amerling R
    Nephrol News Issues; 2007 Jul; 21(8):52, 54-5, 68. PubMed ID: 17688232
    [No Abstract]   [Full Text] [Related]  

  • 2. Has economics overshadowed our clinical approaches to EPO?
    Sullivan JD
    Nephrol News Issues; 2007 Jul; 21(8):56, 58-9, 68. PubMed ID: 17688233
    [No Abstract]   [Full Text] [Related]  

  • 3. Anemia: dialysis patients experiences.
    Schatell D; Witten B
    Nephrol News Issues; 2004 Nov; 18(12):49-54. PubMed ID: 15595502
    [No Abstract]   [Full Text] [Related]  

  • 4. NRAA responds to proposed $1 cut in EPO reimbursement.
    Nephrol News Issues; 1998 Apr; 12(4):12-3. PubMed ID: 9601363
    [No Abstract]   [Full Text] [Related]  

  • 5. Finding a rational approach to ESA therapy--for payers and patients.
    Messana A
    Nephrol News Issues; 2007 Sep; 21(10):54, 56. PubMed ID: 17918481
    [No Abstract]   [Full Text] [Related]  

  • 6. Factors influencing route of administration for epoetin treatment among hemodialysis patients in the United States.
    Thamer M; Zhang Y; Kaufman J; Stefanik K; Cotter DJ
    Am J Kidney Dis; 2006 Jul; 48(1):77-87. PubMed ID: 16797389
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cost-effectiveness analysis of treatment with epoietin-alpha for patients with anaemia due to renal failure: the case of Sweden.
    Glenngård AH; Persson U; Schön S
    Scand J Urol Nephrol; 2008; 42(1):66-73. PubMed ID: 17907051
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Capturing Epogen overfill.
    Wiseman K
    Nephrol Nurs J; 2000 Aug; 27(4):407, 415. PubMed ID: 11276633
    [No Abstract]   [Full Text] [Related]  

  • 9. Finding the magic formula for ESA use.
    Neumann ME
    Nephrol News Issues; 2010 May; 24(6):8. PubMed ID: 20509399
    [No Abstract]   [Full Text] [Related]  

  • 10. Relative mortality and epoetin alpha dose in hemodialysis patients.
    Cotter DJ; Thamer M; Zhang Y
    Am J Kidney Dis; 2008 May; 51(5):865; author reply 865-6. PubMed ID: 18436099
    [No Abstract]   [Full Text] [Related]  

  • 11. Relative mortality and epoetin alpha dose among hemodialysis patients.
    Coyne DW
    Am J Kidney Dis; 2008 May; 51(5):866-7; author reply 867. PubMed ID: 18436101
    [No Abstract]   [Full Text] [Related]  

  • 12. Medicare and erythropoietin.
    Steinbrook R
    N Engl J Med; 2007 Jan; 356(1):4-6. PubMed ID: 17202449
    [No Abstract]   [Full Text] [Related]  

  • 13. Current and future challenges in anaemia management.
    Levin A; Locatelli F; Muirhead N; Ritz E
    Nephrol Dial Transplant; 2005 Jun; 20 Suppl 6():vi1-2. PubMed ID: 15958819
    [No Abstract]   [Full Text] [Related]  

  • 14. Epoetin bubble: a severe German case Honi soit qui mal y pense.
    Wizemann V
    Nephrol Dial Transplant; 2011 May; 26(5):1750-2; author reply 1752. PubMed ID: 21378149
    [No Abstract]   [Full Text] [Related]  

  • 15. Prophylactic recombinant epoetin alfa markedly reduces the need for blood transfusion in patients with metastatic melanoma treated with biochemotherapy.
    Wolchok JD; Klimek VM; Williams L; Chapman PB
    Cytokines Cell Mol Ther; 1999 Dec; 5(4):205-6. PubMed ID: 10850383
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Is it time to reconsider subcutaneous administration of epoetin?
    Patel TV; Robinson K; Singh AK
    Nephrol News Issues; 2007 Oct; 21(11):57, 59, 63-4 passim. PubMed ID: 17970510
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Bundled payment for ESRD--including ESAs in Medicare's dialysis package.
    Iglehart JK
    N Engl J Med; 2011 Feb; 364(7):593-5. PubMed ID: 21323538
    [No Abstract]   [Full Text] [Related]  

  • 18. Revisions in the prescribing information for Epoetin alfa: implications for nephrology nurses and patients on dialysis.
    Hayslip D
    Nephrol Nurs J; 2008; 35(2):163-7. PubMed ID: 18472685
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Erythropoietin claims monitoring policy: implications of the October 2006 update continuing.
    Messana T
    Nephrol Nurs J; 2006; 33(6):660-3; quiz 664-5. PubMed ID: 17219727
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The economic impact of epoetin alfa therapy on delaying time to dialysis in elderly patients with chronic kidney disease.
    Lefebvre P; Duh MS; Mody SH; Bookhart B; Piech CT
    Dis Manag; 2007 Feb; 10(1):37-45. PubMed ID: 17309363
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.